CND Life Sciences
CND Life Sciences is a biotechnology company specializing in diagnostic testing for neurodegenerative diseases. Their flagship product, the Syn-One Test®, utilizes skin biopsy tissue to detect and quantify abnormal alpha-synuclein protein, a key indicator of Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and related disorders.
Leadership & Board
- Current Number of Employees
- 154
- Current LinkedIn Followers
- 4,585
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $17M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $3M
- Latest Funding Round
- Investment
- Post-Money Valuation
- ―
Company Momentum Positive
CND Life Sciences LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
CND Life Sciences had 154 employees as of October 12, 2026. The number of employees increased by 2 (1.32%) week-over-week.
Social Trend
CND Life Sciences had 4,585 followers as of October 12, 2026. The number of followers increased by 20 (0.44%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Nov 22, 2025 | Investment | $3.00M | ― |
| May 01, 2025 | Series A | $13.50M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| National Institutes of Health | Investment |
| Labcorp | Series A |
Similar Companies
A snapshot of private companies similar to CND Life Sciences, helping you discover and navigate related company profiles.
Related News and Analysis
